Structural requirement of RARγ agonism through computational aspects.

Area of Science:

• Medicinal Chemistry
• Molecular Pharmacology
• Computational Drug Design

Background:

• Retinoic Acid Receptor gamma (RARγ) is a validated target for treating skin conditions and has potential in oncology.
• Understanding RARγ agonist interactions is crucial for developing effective therapeutics.

Purpose of the Study:

• To conduct a comprehensive structure-activity relationship (SAR) study of third and fourth-generation RARγ agonists.
• To elucidate the binding mechanism of RARγ agonists using computational approaches.
• To identify key molecular features for rational drug design.

Main Methods:

• Utilized Schrödinger suite 2021-2, Discovery Studio 3.0, LigandScout 4.3, and PyMOL.
• Employed protein-ligand complex analysis, molecular docking, dynamics simulations, MM-GBSA, ASM, and pharmacophore modeling.
• Analyzed crystal structures of RARγ complexes and approved drugs like Adapalene and Trifarotene.

Main Results:

• Identified critical amino acids (Arg267, Ser278, Phe288, Phe230, Met272, Leu271, Leu268) in the RARγ binding pocket.
• Determined essential pharmacophore features: two hydrophobic groups, two aromatic rings, and negative ionic features.
• Elucidated the binding mode of RARγ agonists.

Conclusions:

• The identified SAR and binding mechanism provide a foundation for designing novel RARγ agonists.
• This research aids in the development of targeted therapies for skin diseases and cancers.
• Rational drug design strategies can be enhanced by understanding these molecular interactions.